Boston, MA, United States of America

Michael L Gosselin

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 268(Granted Patents)


Location History:

  • Chelsea, MA (US) (1995 - 1999)
  • Revere, MA (US) (2000)
  • Baltimore, MD (US) (2001)
  • Clinton, CT (US) (2010)
  • Boston, MA (US) (2015 - 2024)

Company Filing History:


Years Active: 1995-2024

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):

Title: The Innovative Contributions of Michael L. Gosselin

Introduction

Michael L. Gosselin is a prominent inventor based in Boston, MA, with a remarkable portfolio of 13 patents to his name. His innovative work primarily focuses on therapeutic antibodies and their applications in treating autoimmune diseases. Gosselin's contributions to the field of biotechnology and pharmaceuticals are significant and reflect his commitment to advancing medical science.

Latest Patents

Among his latest patents, Gosselin has developed nucleic acids encoding anti-TREM-1 antibodies. These antibodies specifically bind to and inhibit the TREM-1 signaling pathway, an important mechanism in the inflammatory response. What's noteworthy is that these antibodies do not engage with one or more Fcγ receptors, thus preventing myeloid cells from producing inflammatory cytokines. The implications of this technology extend to therapeutic applications, particularly in the treatment of autoimmune diseases. His other patent, titled "Anti-TREM-1 antibodies and uses thereof," reinforces his focus on this area, outlining similar technologies and their potential benefits.

Career Highlights

Michael L. Gosselin has achieved considerable success throughout his career, notably working with leading companies such as Bristol-Myers Squibb Company. His tenure at such an esteemed organization has allowed him to not only develop his own innovations but also contribute to broader projects in the biotech and pharmaceutical sectors.

Collaborations

In his journey as an inventor, Gosselin has collaborated with notable coworkers such as Tracy S. Mitchell and David Fabrizio. These partnerships have likely enhanced his inventive processes and broadened the scope of his research efforts.

Conclusion

Michael L. Gosselin exemplifies the spirit of innovation within the biotechnology field. His dedication to developing anti-TREM-1 antibodies demonstrates the potential for groundbreaking therapies in treating autoimmune diseases. With a robust portfolio of patents and a career highlighted by significant collaborations, Gosselin continues to make invaluable contributions to medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…